Cannabis use disorder may increase risk of COVID-19 hospitalization

Researchers in the United States have conducted a study suggesting that genetic vulnerability to a psychiatric syndrome called cannabis use disorder (CUD) may increase the risk of developing severe coronavirus disease 2019 (COVID-19) that requires hospitalization.

Cannabis use disorder (CUD) is a moderately-heritable psychiatric syndrome that is genetically correlated with respiratory disease, says the team.

Using genome-wide associated analysis (GWAS) summary statistics, the researchers identified a partial genetic overlap between vulnerability to CUD and susceptibility to COVID-19 that requires hospitalization.

Further analysis revealed a genomic association between CUD and COVID-19 hospitalization that remained after accounting for potential confounders such as age, smoking status, cardiometabolic traits, and indicators of socioeconomic status.

“Heavy problematic cannabis use may increase chances of hospitalization due to COVID-19 respiratory complications,” write the researchers.

The team – from Washington University in St. Louis and the University of Colorado – says, “curbing excessive cannabis use may be an essential strategy in COVID-19 mitigation.”

A pre-print version of the paper is available on the medRxiv* server, while the article undergoes peer review.

Study: Genetic Liability to Cannabis Use Disorder and COVID-19 Hospitalization. Image Credit: Dmytro Tyshchenko / Shutterstock
Study: Genetic Liability to Cannabis Use Disorder and COVID-19 Hospitalization. Image Credit: Dmytro Tyshchenko / Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Risk of COVID-19 hospitalization could be linked to behavioral factors

Genetic vulnerability to hospitalization following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) – the agent that causes COVID-19 – could be partially linked to comorbid behavioral risk factors, particularly the use of combustible psychoactive substances, say Alexander Hatoum (Washington University School of Medicine) and colleagues.

Reports have shown that over the course of the COVID-19 pandemic, laws that would usually prohibit the use of cannabis have increasingly permitted its recreational use.

On November 3rd, 2020, people in Arizona, Montana, New Jersey, and South Dakota voted to join eleven other states that have already legalized the recreational use of cannabis.

Research has also shown that legalization is associated with the increased use of the substance and that one-fifth of people who have tried cannabis go on to develop cannabis CUD.

Hatoum and team say it has already been demonstrated that CUD is moderately heritable (50-60%) and genetically correlated with the risk of developing respiratory disease.

“As the heterogeneous presentation of COVID-19 is partially attributable to host genomic background and respiratory symptoms are the primary reason for hospitalization and death, genomic liability to CUD may contribute to severe COVID-19 presentation,” write the researchers.

What did the current study involve?

The team used GWAS summary statistics on CUD (14,080 cases; 343,726 controls) and COVID-19 hospitalization (6,492 cases; 1,012,809 population controls) to assess whether genetic susceptibility to CUD could plausibly influence the risk of being hospitalized with COVID-19.

Using linkage disequilibrium score regression analyses, the researchers found that at least one-third of genetic vulnerability to COVID-19 hospitalization overlapped with genetic susceptibility to CUD.

“Genetic causality as a potential mechanism of risk could not be excluded,” say Hatoum and the team.

Using a series of genomic structural equation models, the researchers identified an independent genomic association between CUD and COVID-19 hospitalization, following adjustment for a range of potential confounders.

These variables included genomic susceptibility to tobacco phenotypes (e.g., cigarettes smoked per day, lifetime cannabis use and smoking cessation); cardiometabolic factors (BMI and fasting glucose); socioeconomic status (educational attainment, Townsend deprivation index) and forced expiratory volume.

In addition, latent causal variable analyses provided evidence to support that susceptibility to CUD could be genetically causal for COVID-19 hospitalization.

Highly speculative, but plausible, says the team

The researchers acknowledge that the use of population controls (individuals who may or may not have had COVID-19) in the GWAS may have impacted the precision of the association estimate.

They also acknowledge that the GWAS statistics were mainly generated from samples of genomically-confirmed European ancestry, which may limit the generalizability of the findings to other ancestral populations.

Hatoum and colleagues say that, while highly speculative, it is plausible that heavy and problematic cannabis use associated with CUD could increase the risk of severe COVID-19.

“As the world prepares for surges in COVID-19, identifying putative risk factors associated with severe presentations may mitigate its worldwide impact,” say the researchers.

“In contrast to anecdotal evidence and media reports that cannabis may attenuate COVID-19, these data urge caution in heavy cannabis use during the COVID-19 pandemic,” they conclude.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • Mar 30 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2023, March 30). Cannabis use disorder may increase risk of COVID-19 hospitalization. News-Medical. Retrieved on July 21, 2024 from https://www.news-medical.net/news/20201119/Cannabis-use-disorder-may-increase-risk-of-COVID-19-hospitalization.aspx.

  • MLA

    Robertson, Sally. "Cannabis use disorder may increase risk of COVID-19 hospitalization". News-Medical. 21 July 2024. <https://www.news-medical.net/news/20201119/Cannabis-use-disorder-may-increase-risk-of-COVID-19-hospitalization.aspx>.

  • Chicago

    Robertson, Sally. "Cannabis use disorder may increase risk of COVID-19 hospitalization". News-Medical. https://www.news-medical.net/news/20201119/Cannabis-use-disorder-may-increase-risk-of-COVID-19-hospitalization.aspx. (accessed July 21, 2024).

  • Harvard

    Robertson, Sally. 2023. Cannabis use disorder may increase risk of COVID-19 hospitalization. News-Medical, viewed 21 July 2024, https://www.news-medical.net/news/20201119/Cannabis-use-disorder-may-increase-risk-of-COVID-19-hospitalization.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study links lifetime cannabis use with substance use, mood disorders, celiac, and infectious diseases